Welcome to ExamTopics
ExamTopics Logo
- Expert Verified, Online, Free.
Mail Us[email protected]
Menu
The-Open-Group Discussions
exam questions

Exam OGEA-103 All Questions

View all questions & answers for the OGEA-103 exam
Go to Exam

Exam OGEA-103 topic 1 question 49 discussion

Actual exam question from The Open Group's OGEA-103
Question #: 49
Topic #: 1
[All OGEA-103 Questions]

Please read this scenario prior to answering the question

You are serving as the Lead Architect for an Enterprise Architecture team within a leading multinational biotechnology company. The company works in three major industries including healthcare, crop production, and agriculture. Your team works within the healthcare division.

The healthcare division is developing a new vaccine, and has to demonstrate its effectiveness and safety in a set of clinical trials that satisfy the regulatory requirements of the relevant health authorities. The clinical trials are undertaken by its research laboratories at multiple facilities worldwide. In addition to internal research and development activities, the healthcare division is also involved in publicly funded collaborative research projects with industrial and academic partners.

The Enterprise Architecture team has been engaged in an architecture project to develop a secure system that will allow the healthcare researchers to share information more easily about their clinical trials, and work more collaboratively across the organization and also with its partners. This system will also connect with external partners.

The Enterprise Architecture team uses the TOGAF ADM with extensions required to support healthcare manufacturing practices and laboratory practices. Due to the highly sensitive nature of the information that is managed special care has been taken to ensure that each architecture domain considers the security and privacy issues that are relevant.

The Vice President for Worldwide Clinical Research is the sponsor of the Enterprise Architecture activity. She has stated that disruptions must be minimized for the clinical trials, and that the rollout must be undertaken incremental.


Refer to the scenario -

You have been asked to recommend the approach to identify the work packages for an incremental rollout meeting the requirements.

Based on the TOGAF standard which of the following is the best answer?

  • A. You recommend that the Solution Building Blocks from a Consolidated Gaps, Solutions and Dependencies Matrix be grouped into a set of work packages. Using the matrix as a planning tool regroup the work packages to account for dependencies. Sequence the work packages into the Capability Increments needed to achieve the Target Architecture, so that the implementation team can schedule the rollout one region at a time to minimize disruption. Document the work packages for the Enterprise Architecture using a Transition Architecture State Evolution Table.
  • B. You recommend that the set of required Solution Building Blocks be determined by identifying those which need to be developed and which need to be procured. Eliminate any duplicates. Group the remaining Solution Building Blocks together to create the work packages using a CRUD (create, read, update delete) matrix. Rank the work packages and select the most cost-effective options for inclusion in a series of Transition Architectures Schedule the roll out of the work packages to be sequential across the geographic regions.
  • C. You recommend that an Implementation Factor Catalog is drawn up to indicate actions and constraints. A Consolidated Gaps, Solutions and Dependencies Matrix should also be created. For each gap identify a proposed solution and classify it as new development purchased solution, or based on an existing product. Group similar activities together to form work packages. Identify dependencies between work packages factoring in the clinical trial schedules. Regroup the work packages into a set of Capability Increments scheduled into a series of Transition Architectures.
  • D. You recommend that a Consolidated Gaps, Solutions and Dependencies Matrix is used as a planning tool for creating work packages. For each gap classify whether the solution is either a new development, purchased solution, or based on an existing product. Group the similar solutions together to define the work packages. Regroup the work packages into a set of Capability Increments to transition to the Target Architecture considering the schedule for clinical trials, and document in an Architecture Definition Increments Table.
Show Suggested Answer Hide Answer
Suggested Answer: C 🗳️
by rolandpat at Feb. 24, 2024, 2:45 p.m.

Comments

Chosen Answer:
This is a voting comment (?) , you can switch to a simple comment.
Switch to a voting comment New
Submit Cancel
391db44
3 weeks, 6 days ago
Selected Answer: A
A Looks more complete to me as C does not address the minimizing disruption factor.
upvoted 1 times
...
SubscriberHK
3 months, 3 weeks ago
Selected Answer: C
C seems more complete
upvoted 1 times
...
arye777
5 months, 1 week ago
Selected Answer: A
IMO:A is the best answer. It directly addresses the sponsor's requirement for minimizing disruptions by proposing a well-structured approach to group solutions into work packages, sequence these into Capability Increments tailored for regional rollouts, and document this progression using a Transition Architecture State Evolution Table. This method ensures that the rollout is both structured and aligned with the operational requirements of ongoing clinical trials, making it the most suitable option for achieving the objectives set by the Vice President for Worldwide Clinical Research.
upvoted 2 times
...
rolandpat
9 months ago
Selected Answer: C
While the other options have some merit, they lack key elements: A: While grouping Solution Building Blocks is helpful, it lacks the specific consideration of implementation factors and clinical trial schedules. B: Using CRUD matrix is not recommended for TOGAF, and ranking based solely on cost might not consider strategic priorities. D: While using the matrix and classifying solutions is good, it misses the Implementation Factor Catalog and specific consideration of clinical trial schedules.
upvoted 4 times
...

Get IT Certification

Unlock free, top-quality video courses on ExamTopics with a simple registration. Elevate your learning journey with our expertly curated content. Register now to access a diverse range of educational resources designed for your success. Start learning today with ExamTopics!

Start Learning for free
Community vote distribution
A (35%)
C (25%)
B (20%)
Other
Most Voted
A voting comment increases the vote count for the chosen answer by one.

Upvoting a comment with a selected answer will also increase the vote count towards that answer by one. So if you see a comment that you already agree with, you can upvote it instead of posting a new comment.

SaveCancel